{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:10:54Z","timestamp":1768414254814,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.diabet.2020.09.005","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T05:30:39Z","timestamp":1602135039000},"page":"101196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["SGLT2i as fourth-line therapy and risk of mortality, end-stage renal diseases and cardiovascular diseases in patients with type 2 diabetes mellitus"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6895-6071","authenticated-orcid":false,"given":"C.K.H.","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.H.M.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8645-1942","authenticated-orcid":false,"given":"K.K.C.","family":"Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.W.Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.C.K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.L.K.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.diabet.2020.09.005_bib0005","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.2337\/dc19-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2020.09.005_bib0010","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","article-title":"2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"63","author":"Buse","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2020.09.005_bib0015","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2020.09.005_bib0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2020.09.005_bib0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/2040622317735283","article-title":"Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential","volume":"9","author":"Roder","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.diabet.2020.09.005_bib0030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4158\/CS-2017-0153","article-title":"Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm \u2013 2018 Executive Summary","volume":"24","author":"Garber","year":"2018","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabet.2020.09.005_bib0035","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2020.09.005_bib0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacbts.2018.10.002","article-title":"SGLT2 Inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart","volume":"4","author":"Lim","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.diabet.2020.09.005_bib0045","doi-asserted-by":"crossref","first-page":"k119","DOI":"10.1136\/bmj.k119","article-title":"Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study","volume":"360","author":"Patorno","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2020.09.005_bib0050","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1161\/CIRCULATIONAHA.118.039177","article-title":"Empagliflozin and the risk of heart failure hospitalization in routine clinical care","volume":"139","author":"Patorno","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2020.09.005_bib0055","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2018.01.085","article-title":"SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL","volume":"71","author":"Cavender","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2020.09.005_bib0060","doi-asserted-by":"crossref","first-page":"l4772","DOI":"10.1136\/bmj.l4772","article-title":"Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study","volume":"366","author":"Pasternak","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2020.09.005_bib0065","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","article-title":"Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 Study","volume":"71","author":"Kosiborod","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2020.09.005_bib0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2020.09.005_bib0075","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2018.3024","article-title":"Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"319","author":"Zheng","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2020.09.005_bib0080","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2337\/dc18-1871","article-title":"Reduction of cardiovascular risk and improved estimated glomerular filtration rate by sglt2 inhibitors, including dapagliflozin, is consistent across the class: an analysis of the placebo arm of EXSCEL","volume":"42","author":"Clegg","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2020.09.005_bib0085","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2020.09.005_bib0090","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/dom.13620","article-title":"The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis","volume":"21","author":"Wang","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2020.09.005_bib0095","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2337\/dc18-0588","article-title":"SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management","volume":"41","author":"van Baar","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2020.09.005_bib0100","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.2337\/dc12-0788","article-title":"Metformin and the risk of cancer: time-related biases in observational studies","volume":"35","author":"Suissa","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2020.09.005_bib0105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7326\/M18-1900","article-title":"Excess burden of mental illness and hospitalization in young-onset type 2 diabetes: a population-based cohort study","volume":"170","author":"Ke","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2020.09.005_bib0110","doi-asserted-by":"crossref","first-page":"e1002999","DOI":"10.1371\/journal.pmed.1002999","article-title":"Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: a retrospective cohort study","volume":"16","author":"Wong","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.diabet.2020.09.005_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v045.i04","article-title":"Multiple imputation by chained equations (MICE): implementation in Stata","volume":"45","author":"Royston","year":"2011","journal-title":"J Stat Softw"},{"key":"10.1016\/j.diabet.2020.09.005_bib0120","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.diabet.2020.09.005_bib0125","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jclinepi.2006.01.009","article-title":"Using the outcome for imputation of missing predictor values was preferred","volume":"59","author":"Moons","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.diabet.2020.09.005_bib0130","series-title":"MMWS: Stata module to perform marginal mean weighting through stratification","author":"Linden","year":"2014"},{"key":"10.1016\/j.diabet.2020.09.005_bib0135","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","article-title":"Propensity score methods for confounding control in nonexperimental research","volume":"6","author":"Brookhart","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"10.1016\/j.diabet.2020.09.005_bib0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0962280217713032","article-title":"Propensity score analysis with partially observed covariates: how should multiple imputation be used?","volume":"28","author":"Leyrat","year":"2019","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.diabet.2020.09.005_bib0145","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2018.21554","article-title":"Using the E-Value to assess the potential effect of unmeasured confounding in observational studies","volume":"321","author":"Haneuse","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2020.09.005_bib0150","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363620301476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363620301476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:58:14Z","timestamp":1761130694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363620301476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1262363620301476"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2020.09.005","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2i as fourth-line therapy and risk of mortality, end-stage renal diseases and cardiovascular diseases in patients with type 2 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2020.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101196"}}